Free Trial
NASDAQ:SLNO

Soleno Therapeutics Q2 2024 Earnings Report

Soleno Therapeutics logo
$82.35 +3.64 (+4.62%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$82.91 +0.56 (+0.68%)
As of 08/8/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Soleno Therapeutics EPS Results

Actual EPS
-$0.57
Consensus EPS
-$0.63
Beat/Miss
Beat by +$0.06
One Year Ago EPS
N/A

Soleno Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Soleno Therapeutics Announcement Details

Quarter
Q2 2024
Time
After Market Closes
Conference Call Date
Wednesday, August 7, 2024
Conference Call Time
4:00PM ET

Soleno Therapeutics Earnings Headlines

The Coin That Could Define Trump’s Crypto Presidency
When Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top advisor on crypto and AI. That alone signaled a shift. But insiders close to D.C. aren’t just talking crypto policy—they’re quietly buying something most retail investors have missed. While the crowd chases Bitcoin to $150,000, Weiss Ratings expert Juan Villaverde believes a different coin—already backed by giants like Google, Visa, and PayPal—could soon become crypto’s “Third Giant.”
Soleno Therapeutics's Earnings: A Preview
See More Soleno Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Soleno Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Soleno Therapeutics and other key companies, straight to your email.

About Soleno Therapeutics

Soleno Therapeutics (NASDAQ:SLNO), a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

View Soleno Therapeutics Profile

More Earnings Resources from MarketBeat